About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker INO · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 22, 2026INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) i…
NCT03491683 · Glioblastoma
INO-5401, INO-9012
INO
Inovio Pharmaceuticals
Phase 1/2Active, not recruiting52Dec 31, 2027Registry ↗
Sep 2, 2026INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic…
NCT03502785 · Urothelial Carcinoma
INO-5401, INO-9012
INO
Inovio Pharmaceuticals
Phase 1/2Completed35May 9, 2025Registry ↗
Apr 14, 2026INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent R…
NCT04398433 · Respiratory Papillomatosis
INO-3107, CELLECTRA® 2000
INO
Inovio Pharmaceuticals
Phase 1/2Completed32Dec 15, 2022Registry ↗
Jan 22, 2026Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
NCT04588428 · Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
INO-4700, Placebo
INO
Inovio Pharmaceuticals
Phase 2Completed192Jan 19, 2023Registry ↗
Oct 17, 2024REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03721978 · Cervical Dysplasia, Cervical High Grade Squamous Intraepith…
VGX-3100, Matched Placebo
INO
Inovio Pharmaceuticals
Phase 3Completed203Aug 23, 2022Registry ↗
Dec 20, 2023Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2…
NCT04642638 · Coronavirus Infection, Severe Acute Respiratory Syndrome Co…
INO-4800, CELLECTRA® 2000
INO
Inovio Pharmaceuticals
Phase 2/3Terminated1,307Sep 13, 2022Registry ↗
Aug 25, 2023Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment…
NCT03180684 · Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), V…
VGX-3100, Imiquimod 5% Cream
INO
Inovio Pharmaceuticals
Phase 2Completed33Jul 23, 2020Registry ↗
Jul 27, 2023REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
NCT03185013 · Cervical Dysplasia, Cervical High Grade Squamous Intraepith…
VGX-3100, Placebo
INO
Inovio Pharmaceuticals
Phase 3Completed201Jul 8, 2020Registry ↗
Jul 14, 2023VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-1…
NCT03499795 · Anal Neoplasm
VGX-3100, CELLECTRA™ 5PSP
INO
Inovio Pharmaceuticals
Phase 2Completed23Jun 16, 2020Registry ↗
Nov 21, 2022Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Gh…
NCT04093076 · Lassa Fever
INO-4500, CELLECTRA™ 2000
INO
Inovio Pharmaceuticals
Phase 1Completed220Oct 14, 2022Registry ↗
Nov 17, 2022Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
NCT05430958 · Coronavirus Infection
INO-4800, INO-9112
INO
Inovio Pharmaceuticals
Phase 1Withdrawn0Mar 2024Registry ↗
Apr 15, 2022Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
NCT04336410 · Coronavirus Infection
INO-4800, CELLECTRA® 2000
INO
Inovio Pharmaceuticals
Phase 1Completed120Feb 10, 2022Registry ↗
Mar 4, 2022Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carci…
NCT00198328 · Head Neck Cancer
Medpulser Electroporation with Bleomycin, Surgical Excision
INO
Inovio Pharmaceuticals
Phase 3Terminated84Jun 2007Registry ↗
Mar 4, 2022Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcin…
NCT00198315 · Head and Neck Cancer
Medpulser electroporation with Bleomycin, Tumor surgical ex…
INO
Inovio Pharmaceuticals
Phase 3Terminated130Jun 2007Registry ↗
Feb 21, 2021A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
NCT02172911 · Cervical Cancer
INO-3112, CELLECTRA™-5P
INO
Inovio Pharmaceuticals
Phase 1/2Completed10Sep 7, 2017Registry ↗
Jan 22, 2021Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell…
NCT02163057 · Head and Neck Squamous Cell Cancer
INO-3112, CELLECTRA™-5P
INO
Inovio Pharmaceuticals
Phase 1/2Completed22Jan 23, 2017Registry ↗
Nov 23, 2020Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
NCT03805984 · Lassa Fever
INO-4500, Placebo
INO
Inovio Pharmaceuticals
Phase 1Completed60Oct 21, 2020Registry ↗
Oct 15, 2019Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
NCT02431312 · Hepatitis B
INO-1800, INO-9112
INO
Inovio Pharmaceuticals
Phase 1Completed90May 22, 2018Registry ↗
Jun 28, 2019Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electropor…
NCT02464670 · Ebola Vaccine
INO-4201, INO-4202
INO
Inovio Pharmaceuticals
Phase 1Completed240May 24, 2018Registry ↗
Nov 19, 2018hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults Wi…
NCT02960594 · Breast Cancer, Lung Cancer
INO-1400, INO-9012
INO
Inovio Pharmaceuticals
Phase 1Completed93Nov 9, 2018Registry ↗
Nov 16, 2018Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
NCT02241369 · Aerodigestive Precancerous Lesions and Malignancies
INO-3106, INO-9012
INO
Inovio Pharmaceuticals
Phase 1Completed3Sep 2018Registry ↗
Sep 7, 2018A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neop…
NCT01304524 · Cervical Intraepithelial Neoplasia
VGX 3100, Placebo
INO
Inovio Pharmaceuticals
Phase 2Completed167May 2014Registry ↗
Aug 10, 2018Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously V…
NCT01188850 · Human Papillomavirus (HPV)
VGX-3100
INO
Inovio Pharmaceuticals
Phase 1Completed14Oct 2011Registry ↗
Dec 26, 2017Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate…
NCT02514213 · Prostate Cancer
2mg INO-5150 and electroporation device CELLECTRA®-5P, 8.5m…
INO
Inovio Pharmaceuticals
Phase 1Completed62Dec 12, 2017Registry ↗
Oct 3, 2017Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous…
NCT00198276 · Cancer
MedPulser Electroporation with bleomycin
INO
Inovio Pharmaceuticals
Phase 4Completed88Sep 2008Registry ↗
Oct 3, 2017Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck Cancer
NCT00198263 · Head and Neck Cancer
Medpulser Electroporation with Bleomycin
INO
Inovio Pharmaceuticals
Phase 4Completed95Sep 2008Registry ↗
Sep 13, 2017A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001
NCT01403155 · Healthy
INO-3401 + EP
INO
Inovio Pharmaceuticals
Phase 1Completed22Aug 2012Registry ↗
Sep 13, 2017Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults
NCT01142362 · Healthy
VGX-3400X
INO
Inovio Pharmaceuticals
Phase 1Completed32Nov 2011Registry ↗
Sep 13, 2017Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3
NCT00685412 · Papillomavirus Infections
VGX-3100
INO
Inovio Pharmaceuticals
Phase 1Completed18Jan 2011Registry ↗

29 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:06 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances